HIV is both an epidemic and a pandemic, depending on the scale you’re looking at. Globally, it qualifies as a pandemic because it affects populations across multiple continents simultaneously. Within individual countries or regions, it operates as an epidemic, with concentrated outbreaks that vary widely in severity. As of 2024, roughly 40.8 million people worldwide are living with HIV, and about 1.3 million new infections still occur each year.
Epidemic, Pandemic, or Endemic
These three terms describe different patterns of disease spread, and HIV has moved through more than one category over its history. An epidemic refers to a disease spreading rapidly through a specific population or region at rates higher than expected. A pandemic is an epidemic that crosses international borders and affects large numbers of people across multiple countries or continents. Endemic describes a disease that persists in a population at a relatively stable, predictable rate.
When HIV first emerged in the early 1980s, it began as localized epidemics in specific communities. By the late 1980s and 1990s, it had spread to every continent and was recognized as a full pandemic. Today, major global health bodies including the WHO, UNAIDS, and the Global Fund still treat HIV as an ongoing pandemic, with aligned strategies aimed at ending the HIV epidemic by 2030. That language is deliberate: while treatment has transformed HIV from a death sentence into a manageable chronic condition for millions, the virus is still spreading fast enough in many parts of the world to maintain its epidemic classification.
Some researchers have begun discussing whether HIV could eventually transition from pandemic levels to “low-level endemicity,” meaning new infections would drop to a low, stable baseline rather than surging through populations. A framework published in The Lancet outlined how combining behavioral prevention, condom use, expanded antiretroviral treatment, and pre-exposure prophylaxis could theoretically achieve this shift. But that transition hasn’t happened yet on a global scale.
Where the Numbers Stand Today
HIV has claimed an estimated 44.1 million lives since the beginning of the pandemic. The toll continues, with 630,000 people dying from HIV-related causes in 2024 alone. That said, the trajectory has improved dramatically. Global HIV-related deaths in 2024 were 70% lower than at their peak in 2004, largely because antiretroviral therapy became widely available in low- and middle-income countries during the 2000s and 2010s.
New infections have also declined but at a slower pace than deaths. The 1.3 million new infections recorded in 2024 represent significant progress compared to the peak years, yet the number has plateaued in some regions and even risen in others. Sub-Saharan Africa still carries the heaviest burden of any region, though parts of Eastern Europe, Central Asia, the Middle East, and North Africa have seen rising infection rates in recent years. The epidemic is not shrinking uniformly.
The Situation in the United States
Within the U.S., HIV is treated as an active epidemic. The federal government launched the “Ending the HIV Epidemic in the U.S.” initiative with specific targets: reducing new infections by 75% by 2025 and by 90% by 2030. These goals center on scaling up prevention tools like pre-exposure prophylaxis and ensuring that people diagnosed with HIV start and stay on treatment quickly enough to suppress the virus to undetectable levels, which prevents transmission.
New infections in the U.S. are heavily concentrated in specific populations and geographic areas. The majority occur in the South, and men who have sex with men, Black and Latino communities, and transgender women face disproportionately high rates. This pattern of concentrated spread within certain groups is characteristic of an epidemic rather than a disease that affects the general population evenly.
Why HIV Hasn’t Become Endemic Yet
For HIV to shift from epidemic to endemic status, new infections would need to fall to a low, stable rate that health systems can absorb without emergency-level intervention. Several factors keep this from happening. First, roughly 14% of the 40.8 million people living with HIV globally don’t know they’re infected, which means they aren’t on treatment and can unknowingly transmit the virus. Second, access to prevention and treatment remains uneven. Wealthier countries and urban areas tend to have strong programs, while rural communities and countries with fewer resources lag behind.
Stigma also plays a persistent role. In many settings, fear of discrimination prevents people from getting tested or seeking care. Criminalization of sex work, drug use, and same-sex relationships in dozens of countries pushes the populations most affected by HIV further from health services. These structural barriers mean that even where effective tools exist, they don’t always reach the people who need them most.
There is also no cure and no vaccine widely available, which distinguishes HIV from diseases like smallpox or polio where elimination was achievable through immunization campaigns. Lifelong treatment suppresses the virus effectively but requires consistent access to medication and healthcare, something that remains fragile in many parts of the world.
What “Ending the Epidemic” Actually Means
When organizations talk about ending the HIV epidemic, they don’t mean eradicating the virus entirely. They mean reducing new infections and deaths to low enough levels that HIV no longer constitutes a public health crisis. The practical benchmark most often cited is fewer than 200,000 new infections per year globally and universal access to treatment for everyone living with HIV. At 1.3 million new infections annually, the world is still far from that threshold.
The tools to get there already exist. Antiretroviral treatment, when taken consistently, suppresses the virus so effectively that a person with an undetectable viral load cannot transmit HIV sexually. Pre-exposure prophylaxis reduces the risk of acquiring HIV by about 99% when taken as prescribed. Newer long-acting injectable options are making prevention more accessible for people who find daily pills difficult to maintain. The challenge is not a lack of medical technology but a gap in delivery, funding, and political will.